Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Please note, this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Multiple Myeloma and Bone Disease

Diagnosing Bone Disease

Impact of Bone Disease

Pathophysiology of Bone Disease in MM

Bone-Modifying Agents

Myeloma IX Trial Study Design

Myeloma IX Trial Impact of ZA on Survival

Myeloma IX Trial Impact of ZA on SREs

Non-Inferiority Study of Denosumab vs ZA Study Design

Non-Inferiority Study of Denosumab vs ZA SREs and PFS

Key Treatment-Emergent Adverse Events

Reversibility of Bone Modifying Agents

ASCO and NCCN Guidelines for Treatment With BMAs

Treatment Duration With Bisphosphonates

Treatment Duration With Bisphosphonates (cont)

Managing AEs Induced by BMAs Expert Opinion

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)